BIEL / Electrome: The Medvi Playbook in Motion
Medvi went from $20,000 to $1.8B (ref. NYT article - How Matt Gallagher Grew Medvi From $20,000 to $1.8 Billion Using AI) because it stopped acting like a device company and started acting like AI‑infrastructure for healthcare.
That’s the exact same structural shift happening with BIEL + Electrome — just earlier on the curve, the correlation follows:
1. Medvi scaled by turning manual healthcare tasks into AI‑automated workflows
Medvi replaced human intake, triage, scheduling, billing, and routing with AI agents.
This allowed them to scale without adding headcount.
BIEL/Electrome parallel:
Electrome is doing the same thing — but with pain management and neuromodulation instead of clinic logistics.
AI‑driven pain assessment
AI‑guided therapy recommendations
Automated treatment tracking
Data‑driven optimization of ActiPatch/RecoveryRx usage
Continuous feedback loops that improve outcomes
BIEL’s devices become the data‑generating hardware layer that feeds Electrome’s AI engine.
This is the same “AI + hardware = exponential scale” formula that made Medvi explode.
2. Medvi succeeded because it was asset‑light and infinitely scalable
Once the AI was built, every new clinic added almost zero marginal cost.
BIEL/Electrome parallel:
BIEL’s patches are:
low‑cost
high‑margin
FDA‑cleared
manufacturable at scale
already validated by 30 years of clinical data
Electrome doesn’t need to build factories, hospitals, or physical infrastructure.
They scale by deploying BIEL’s hardware + Electrome’s software into:
VA hospitals
retail pharmacies
telehealth networks
employer health plans
chronic pain programs
This is the same “software‑scaled healthcare” model that turned Medvi into a unicorn.
3. Medvi’s value came from data — not devices
The more patients used the platform, the smarter the AI became.
That data flywheel is what investors ultimately valued.
BIEL/Electrome parallel:
Every ActiPatch / RecoveryRx unit becomes a data node.
Electrome collects:
usage patterns
pain‑response curves
therapy adherence
demographic correlations
outcome improvements
This creates a bioelectronic medicine dataset that no competitor has.
Data is the moat.
AI is the multiplier.
BIEL’s hardware is the on‑ramp.
This is the same flywheel that took Medvi from $20k to $1.8B.
4. Medvi broke out when it landed major institutional partners
The VA, insurers, and large health systems validated the model and unlocked scale.
BIEL/Electrome parallel:
Electrome already has:
VA deployments
national retail rollout (3,700 pharmacies)
AI‑driven platform integrations
OEM alignment with BIEL
This is the same institutional‑validation moment Medvi had right before its valuation hockey‑stick.
5. Medvi’s investors won because the market mispriced the early inflection point
Most people saw a “small healthtech startup.”
They missed the AI‑infrastructure transformation happening underneath.
BIEL/Electrome parallel:
Most people still see:
“a penny‑stock device maker” (BIEL)
“a small AI health startup” (Electrome)
They’re missing the platform transition:
BIEL evolves from a device seller → to a core OEM + data infrastructure provider.
Electrome evolves from a startup → to an AI‑powered pain‑management ecosystem.
This is the exact same mispricing window Medvi had before its breakout.
Summary
BIEL / Electrome: The Medvi Playbook Is Happening Again
Medvi went from $20k to $1.8B by doing one thing right:
It turned healthcare tasks into AI‑automated workflows and scaled like software, not like a clinic.
BIEL + Electrome are now following the same blueprint — but in pain management and bioelectronic medicine.
Here’s the correlation:
Medvi used AI to automate intake, triage, routing -
Electrome uses AI to automate pain assessment, therapy guidance, and treatment optimization.
Medvi scaled with asset‑light infrastructure -
BIEL’s patches give Electrome a low‑cost, high‑margin hardware layer that scales infinitely.
Medvi’s value came from data -
Every ActiPatch/RecoveryRx becomes a data node feeding Electrome’s AI engine.
Medvi broke out after institutional adoption →
Electrome already has VA deployments and a 3,700‑store retail rollout.
Medvi was mispriced before its inflection →
BIEL/Electrome are in that same window right now.
This is the early stage of an AI‑driven healthcare platform shift.
BIEL provides the hardware.
Electrome provides the AI.
Together they create the same exponential scaling conditions that made Medvi a unicorn.
If Medvi proved anything, it’s this:
AI + healthcare + data flywheel = explosive value creation.
BIEL/Electrome are positioned to run the same play — with a much larger addressable market.
Medvi went from $20,000 to $1.8B (ref. NYT article - How Matt Gallagher Grew Medvi From $20,000 to $1.8 Billion Using AI) because it stopped acting like a device company and started acting like AI‑infrastructure for healthcare.
That’s the exact same structural shift happening with BIEL + Electrome — just earlier on the curve, the correlation follows:
1. Medvi scaled by turning manual healthcare tasks into AI‑automated workflows
Medvi replaced human intake, triage, scheduling, billing, and routing with AI agents.
This allowed them to scale without adding headcount.
BIEL/Electrome parallel:
Electrome is doing the same thing — but with pain management and neuromodulation instead of clinic logistics.
AI‑driven pain assessment
AI‑guided therapy recommendations
Automated treatment tracking
Data‑driven optimization of ActiPatch/RecoveryRx usage
Continuous feedback loops that improve outcomes
BIEL’s devices become the data‑generating hardware layer that feeds Electrome’s AI engine.
This is the same “AI + hardware = exponential scale” formula that made Medvi explode.
2. Medvi succeeded because it was asset‑light and infinitely scalable
Once the AI was built, every new clinic added almost zero marginal cost.
BIEL/Electrome parallel:
BIEL’s patches are:
low‑cost
high‑margin
FDA‑cleared
manufacturable at scale
already validated by 30 years of clinical data
Electrome doesn’t need to build factories, hospitals, or physical infrastructure.
They scale by deploying BIEL’s hardware + Electrome’s software into:
VA hospitals
retail pharmacies
telehealth networks
employer health plans
chronic pain programs
This is the same “software‑scaled healthcare” model that turned Medvi into a unicorn.
3. Medvi’s value came from data — not devices
The more patients used the platform, the smarter the AI became.
That data flywheel is what investors ultimately valued.
BIEL/Electrome parallel:
Every ActiPatch / RecoveryRx unit becomes a data node.
Electrome collects:
usage patterns
pain‑response curves
therapy adherence
demographic correlations
outcome improvements
This creates a bioelectronic medicine dataset that no competitor has.
Data is the moat.
AI is the multiplier.
BIEL’s hardware is the on‑ramp.
This is the same flywheel that took Medvi from $20k to $1.8B.
4. Medvi broke out when it landed major institutional partners
The VA, insurers, and large health systems validated the model and unlocked scale.
BIEL/Electrome parallel:
Electrome already has:
VA deployments
national retail rollout (3,700 pharmacies)
AI‑driven platform integrations
OEM alignment with BIEL
This is the same institutional‑validation moment Medvi had right before its valuation hockey‑stick.
5. Medvi’s investors won because the market mispriced the early inflection point
Most people saw a “small healthtech startup.”
They missed the AI‑infrastructure transformation happening underneath.
BIEL/Electrome parallel:
Most people still see:
“a penny‑stock device maker” (BIEL)
“a small AI health startup” (Electrome)
They’re missing the platform transition:
BIEL evolves from a device seller → to a core OEM + data infrastructure provider.
Electrome evolves from a startup → to an AI‑powered pain‑management ecosystem.
This is the exact same mispricing window Medvi had before its breakout.
Summary
BIEL / Electrome: The Medvi Playbook Is Happening Again
Medvi went from $20k to $1.8B by doing one thing right:
It turned healthcare tasks into AI‑automated workflows and scaled like software, not like a clinic.
BIEL + Electrome are now following the same blueprint — but in pain management and bioelectronic medicine.
Here’s the correlation:
Medvi used AI to automate intake, triage, routing -
Electrome uses AI to automate pain assessment, therapy guidance, and treatment optimization.
Medvi scaled with asset‑light infrastructure -
BIEL’s patches give Electrome a low‑cost, high‑margin hardware layer that scales infinitely.
Medvi’s value came from data -
Every ActiPatch/RecoveryRx becomes a data node feeding Electrome’s AI engine.
Medvi broke out after institutional adoption →
Electrome already has VA deployments and a 3,700‑store retail rollout.
Medvi was mispriced before its inflection →
BIEL/Electrome are in that same window right now.
This is the early stage of an AI‑driven healthcare platform shift.
BIEL provides the hardware.
Electrome provides the AI.
Together they create the same exponential scaling conditions that made Medvi a unicorn.
If Medvi proved anything, it’s this:
AI + healthcare + data flywheel = explosive value creation.
BIEL/Electrome are positioned to run the same play — with a much larger addressable market.
1